- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03675100
Neurotrophic Factors, Tight Junction Proteins, and Cytokines in IBS
March 21, 2020 updated by: Nayoung Kim, Seoul National University Bundang Hospital
Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex
To evaluate the role of neurotrophic factors (NGF, GDNF, TRPV-1), to quantity tight junction proteins (ZO-1, occludin, claudin) and cytokines (IL-8, TNF-a, IL-1b) in the colonic mucosa of IBS patients and also clarify sex differences in the pathophysiology of IBS.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Control group Those who were between 18 and 80 years old and did not have any abnormalities in colonoscopy
- Irritable bowel syndrome group Patients who diagnosed as irritable bowel syndrome according to the ROME III criteria
Exclusion Criteria:
- history of IBD
- abdominal operation
- severe systemic disease
- malignancy,
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: IBS group
Patients who were diagnosed with IBS according to the ROME III criteria.
Colonoscopic mucosal biopsy was undertaken for every subject.
|
colonoscopic mucosal biopsy was undertaken for every participant
|
Active Comparator: Control group
Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality.
Colonoscopic mucosal biopsy was undertaken for every subject.
|
colonoscopic mucosal biopsy was undertaken for every participant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NGF, GDNF, and TRPV-1 mRNA expression of colonic mucosa
Time Frame: up to 24 weeks
|
real-time qPCR
|
up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ZO-1, Occludin, and Claudin mRNA expression of colonic mucosa
Time Frame: up to 24 weeks
|
real-time qPCR and Western blot
|
up to 24 weeks
|
IL-8, TNF-a, and IL-1b mRNA expression of colonic mucosa
Time Frame: up to 24 weeks
|
real-time qPCR
|
up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nayoung Kim, Professor, Seoul National University Bundang Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2009
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
December 1, 2019
Study Registration Dates
First Submitted
September 11, 2018
First Submitted That Met QC Criteria
September 15, 2018
First Posted (Actual)
September 18, 2018
Study Record Updates
Last Update Posted (Actual)
March 24, 2020
Last Update Submitted That Met QC Criteria
March 21, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-1305/202-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on colonoscopic mucosal biopsy
-
University of British ColumbiaRecruitingColon Adenoma | Colon Polyp | Colon LesionCanada
-
King Chulalongkorn Memorial HospitalRecruiting
-
King Chulalongkorn Memorial HospitalRecruiting
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Seoul National University Bundang HospitalCompletedGastro-esophageal Reflux DiseaseKorea, Republic of
-
Hillel Yaffe Medical CenterUnknown
-
National Cheng-Kung University HospitalRecruitingEsophageal Cancer | Microbial Colonization | Oropharyngeal Neoplasms | Synchronous NeoplasmTaiwan
-
Shandong UniversityCompletedHyperplasia | Colorectal Neoplasia | Mucosal Microbiome | Colorectal InflammationChina
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
Mansoura UniversityCompletedColorectal Carcinoma | Enteropathogenic Escherichia Coli .Egypt